Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:40:52 27/06/2024 pm IST			5-day change	1st Jan Change
4.605 ^USD	-1.81%		-7.83%	+63.35%

01/06	Black Diamond Therapeutics, Inc. Presents Promising Bdtx-1535 Clinical Data in Patients with Recurrent Glioblastoma At 2024 American Society of Clinical Oncology Annual Meeting	CI
16/05	HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating	MT

Black Diamond Therapeutics, Inc. Announces Mark Velleca to Board of Directors

August 10, 2021 at 05:15 pm IST

Black Diamond Therapeutics, Inc. announced the appointment of Mark A. Velleca, M.D., Ph.D. to its Board of Directors. Dr. Velleca brings over 20 years of leadership experience in the biotechnology industry, particularly in the field of oncology, most recently serving as Chief Executive Officer of G1 Therapeutics.

Latest news about Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. Presents Promising Bdtx-1535 Clinical Data in Patients with Recurrent Glioblastoma At 2024 American Society of Clinical Oncology Annual Meeting	01/06	CI
HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating	16/05	MT
Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Black Diamond Therapeutics, Inc. Announces Board and Committee Changes	11/04	CI
Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating	08/04	MT
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients	08/04	MT
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03	CI
Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board	19/01	CI
Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM	13/12	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11	CI
Black Diamond Therapeutics, Inc. Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535	14/23/14	CI
Black Diamond Therapeutics, Inc. Announces Management Changes	18/23/18	CI
Black Diamond Therapeutics, Inc. Announces Chief Executive Officer Changes	18/23/18	CI
Black Diamond Therapeutics, Inc. Doses First Patients in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer	11/23/11	CI
Certain Restricted Stock Units of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023.	29/23/29	CI
Certain Warrants of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023.	29/23/29	CI
Certain Stock Options of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023.	29/23/29	CI
Certain Common Stock of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023.	29/23/29	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target	14/23/14	MT
Sector Update: Health Care Stocks Steady Premarket Monday	10/23/10	MT
Black Diamond Therapeutics Discloses Institutional Shareholder Equity Stake Expansion; Shares Jump Premarket	10/23/10	MT
Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2	30/23/30	MT
Black Diamond Therapeutics Prices $75 Million Common Stock Offering	30/23/30	MT

Chart Black Diamond Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Companyâs MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.69 USD

Average target price

12.6 USD

Spread / Average Target

+168.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BLACK DIAMOND THERAPEUTICS, INC.	+63.35%	264M
VERTEX PHARMACEUTICALS INCORPORATED	+16.67%	122B
REGENERON PHARMACEUTICALS, INC.	+19.61%	115B
ARGENX SE	+21.22%	26.64B
BIONTECH SE	-23.23%	19.91B
GENMAB A/S	-17.47%	16.32B
WUXI APPTEC CO., LTD.	-45.95%	15.52B
BEIGENE, LTD.	-18.26%	15.49B
SAREPTA THERAPEUTICS, INC.	+59.89%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+3.18%	13.67B

Bio Therapeutic Drugs